Q1 Earnings Forecast for REGENXBIO Issued By Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for REGENXBIO in a report released on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar expects that the biotechnology company will earn $0.65 per share for the quarter. The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO's Q3 2025 earnings at $2.03 EPS and Q4 2025 earnings at ($1.44) EPS.

Other analysts have also issued research reports about the company. HC Wainwright reduced their target price on REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a research note on Monday, March 17th. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. The Goldman Sachs Group lowered their price objective on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday. Raymond James began coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an "outperform" rating and a $27.00 target price on the stock. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $31.63.

REGENXBIO Stock Down 3.6 %

RGNX traded down $0.22 during trading on Thursday, reaching $5.94. The company had a trading volume of 649,002 shares, compared to its average volume of 802,506. The business has a 50 day simple moving average of $6.81 and a 200-day simple moving average of $8.14. The stock has a market cap of $297.69 million, a P/E ratio of -1.18 and a beta of 1.26. REGENXBIO has a 52 week low of $5.04 and a 52 week high of $17.52.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The firm had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its position in shares of REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after purchasing an additional 1,659,206 shares during the last quarter. Millennium Management LLC raised its stake in shares of REGENXBIO by 406.3% in the fourth quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company's stock worth $10,222,000 after purchasing an additional 1,061,187 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in shares of REGENXBIO during the fourth quarter worth about $3,865,000. Norges Bank acquired a new stake in shares of REGENXBIO during the fourth quarter worth about $3,474,000. Finally, Cubist Systematic Strategies LLC purchased a new stake in REGENXBIO in the fourth quarter valued at approximately $2,793,000. 88.08% of the stock is currently owned by hedge funds and other institutional investors.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.